These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34328574)

  • 21. A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Cells; 2024 Mar; 13(5):. PubMed ID: 38474414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in Urinary Uric Acid Concentration after Dotinurad Administration to Patients with Hyperuricemia: A Post Hoc Analysis of Two Clinical Trials in Japan.
    Takahashi T; Sasaki M; Shimizu T; Yamaguchi S
    Clin Pharmacol Drug Dev; 2024 Jan; 13(1):87-95. PubMed ID: 37559414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacological properties and clinical efficacy of dotinurad (URECE
    Taniguchi T; Ashizawa N
    Nihon Yakurigaku Zasshi; 2020; 155(6):426-434. PubMed ID: 33132262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor.
    Omura K; Miyata K; Kobashi S; Ito A; Fushimi M; Uda J; Sasaki T; Iwanaga T; Ohashi T
    Drug Metab Pharmacokinet; 2020 Jun; 35(3):313-320. PubMed ID: 32327267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unique Binding Sites of Uricosuric Agent Dotinurad for Selective Inhibition of Renal Uric Acid Reabsorptive Transporter URAT1.
    Fujita K; Isozumi N; Zhu Q; Matsubayashi M; Taniguchi T; Arakawa H; Shirasaka Y; Mori E; Tamai I
    J Pharmacol Exp Ther; 2024 Jun; 390(1):99-107. PubMed ID: 38670801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Uric Acid Lowering on Renin-Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial.
    McMullan CJ; Borgi L; Fisher N; Curhan G; Forman J
    Clin J Am Soc Nephrol; 2017 May; 12(5):807-816. PubMed ID: 28320765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects.
    Nakatani H; Fushimi M; Sasaki T; Okui D; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):8-16. PubMed ID: 31889230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis.
    Li YJ; Chen LR; Yang ZL; Wang P; Jiang FF; Guo Y; Qian K; Yang M; Yin SJ; He GH
    Clin Rheumatol; 2023 Jan; 42(1):215-224. PubMed ID: 36036279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study.
    Yanai H; Katsuyama H; Hakoshima M; Adachi H
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Dotinurad in Hyperuricemic Patients With or Without Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Iqbal A; Iqbal K; Farid E; Ishaque A; Hasanain M; Bin Arif T; Arshad Ali S; Rathore SS; Malik M
    Cureus; 2021 Apr; 13(4):e14428. PubMed ID: 33996294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males.
    Furihata K; Nagasawa K; Hagino A; Kumagai Y
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):36-43. PubMed ID: 32076889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers.
    Motoki K; Igarashi T; Omura K; Nakatani H; Iwanaga T; Tamai I; Ohashi T
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00533. PubMed ID: 31788318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease.
    Fujimori S; Ooyama K; Ooyama H; Moromizato H
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1035-8. PubMed ID: 22132953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mangiferin Inhibits Renal Urate Reabsorption by Modulating Urate Transporters in Experimental Hyperuricemia.
    Yang H; Gao L; Niu Y; Zhou Y; Lin H; Jiang J; Kong X; Liu X; Li L
    Biol Pharm Bull; 2015; 38(10):1591-8. PubMed ID: 26228630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Urate Lowering Therapy on Renal Disease Progression in Hyperuricemic Patients with Chronic Kidney Disease.
    Kim Y; Shin S; Kim K; Choi S; Lee K
    J Rheumatol; 2015 Nov; 42(11):2143-8. PubMed ID: 26428209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.
    Kanbay M; Huddam B; Azak A; Solak Y; Kadioglu GK; Kirbas I; Duranay M; Covic A; Johnson RJ
    Clin J Am Soc Nephrol; 2011 Aug; 6(8):1887-94. PubMed ID: 21784838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum uric acid levels and long-term outcomes in chronic kidney disease.
    Miyaoka T; Mochizuki T; Takei T; Tsuchiya K; Nitta K
    Heart Vessels; 2014 Jul; 29(4):504-12. PubMed ID: 23929090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
    Levy G; Shi JM; Cheetham TC; Rashid N
    Perm J; 2018; 22():17-142. PubMed ID: 30201087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models.
    Li X; Yan Z; Tian J; Zhang X; Han H; Ye F
    Ann Clin Lab Sci; 2019 Nov; 49(6):756-762. PubMed ID: 31882426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy.
    Borges RL; Hirota AH; Quinto BM; Ribeiro AB; Zanella MT; Batista MC
    J Clin Hypertens (Greenwich); 2009 May; 11(5):253-9. PubMed ID: 19534022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.